U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Macroglobulinemia, Waldenstrom, 2(WM2)

MedGen UID:
355856
•Concept ID:
C1864876
•
Finding
Synonym: Macroglobulinemia, Waldenstrom, susceptibility to, 2
 
Monarch Initiative: MONDO:0012491
OMIM®: 610430

Professional guidelines

PubMed

Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol 2023 Feb;98(2):348-358. Epub 2023 Jan 1 doi: 10.1002/ajh.26796. PMID: 36588395Free PMC Article
Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline.
Pratt G, El-Sharkawi D, Kothari J, D'Sa S, Auer R, McCarthy H, Krishna R, Miles O, Kyriakou C, Owen R
Br J Haematol 2022 Apr;197(2):171-187. Epub 2022 Jan 12 doi: 10.1111/bjh.18036. PMID: 35020191
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol 2021 Feb 1;96(2):258-269. doi: 10.1002/ajh.26082. PMID: 33368476

Recent clinical studies

Etiology

Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol 2023 Feb;98(2):348-358. Epub 2023 Jan 1 doi: 10.1002/ajh.26796. PMID: 36588395Free PMC Article
Venetoclax in Previously Treated Waldenström Macroglobulinemia.
Castillo JJ, Allan JN, Siddiqi T, Advani RH, Meid K, Leventoff C, White TP, Flynn CA, Sarosiek S, Branagan AR, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Xu L, Yang G, Patterson CJ, Hunter ZR, Davids MS, Furman RR, Treon SP
J Clin Oncol 2022 Jan 1;40(1):63-71. Epub 2021 Nov 18 doi: 10.1200/JCO.21.01194. PMID: 34793256Free PMC Article
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol 2021 Feb 1;96(2):258-269. doi: 10.1002/ajh.26082. PMID: 33368476
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Sanz RG, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous JV, Motta M, Siddiqi T, Tani M, Trneny M, Minnema MC, Buske C, Leblond V, Trotman J, Chan WY, Schneider J, Ro S, Cohen A, Huang J, Dimopoulos M
Blood 2020 Oct 29;136(18):2038-2050. doi: 10.1182/blood.2020006844. PMID: 32731259Free PMC Article
Ibrutinib in previously treated Waldenström's macroglobulinemia.
Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH
N Engl J Med 2015 Apr 9;372(15):1430-40. doi: 10.1056/NEJMoa1501548. PMID: 25853747

Diagnosis

Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol 2023 Feb;98(2):348-358. Epub 2023 Jan 1 doi: 10.1002/ajh.26796. PMID: 36588395Free PMC Article
Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia.
Gertz MA
Hematol Oncol Clin North Am 2022 Apr;36(2):341-352. Epub 2022 Mar 11 doi: 10.1016/j.hoc.2021.11.001. PMID: 35282954Free PMC Article
Venetoclax in Previously Treated Waldenström Macroglobulinemia.
Castillo JJ, Allan JN, Siddiqi T, Advani RH, Meid K, Leventoff C, White TP, Flynn CA, Sarosiek S, Branagan AR, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Xu L, Yang G, Patterson CJ, Hunter ZR, Davids MS, Furman RR, Treon SP
J Clin Oncol 2022 Jan 1;40(1):63-71. Epub 2021 Nov 18 doi: 10.1200/JCO.21.01194. PMID: 34793256Free PMC Article
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol 2021 Feb 1;96(2):258-269. doi: 10.1002/ajh.26082. PMID: 33368476
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, Arcaini L, Pinkus GS, Rodig SJ, Sohani AR, Harris NL, Laramie JM, Skifter DA, Lincoln SE, Hunter ZR
N Engl J Med 2012 Aug 30;367(9):826-33. doi: 10.1056/NEJMoa1200710. PMID: 22931316

Therapy

Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol 2023 Feb;98(2):348-358. Epub 2023 Jan 1 doi: 10.1002/ajh.26796. PMID: 36588395Free PMC Article
Updates on the Diagnosis and Management of Cold Autoimmune Hemolytic Anemia.
Gertz MA
Hematol Oncol Clin North Am 2022 Apr;36(2):341-352. Epub 2022 Mar 11 doi: 10.1016/j.hoc.2021.11.001. PMID: 35282954Free PMC Article
Venetoclax in Previously Treated Waldenström Macroglobulinemia.
Castillo JJ, Allan JN, Siddiqi T, Advani RH, Meid K, Leventoff C, White TP, Flynn CA, Sarosiek S, Branagan AR, Demos MG, Guerrera ML, Kofides A, Liu X, Munshi M, Tsakmaklis N, Xu L, Yang G, Patterson CJ, Hunter ZR, Davids MS, Furman RR, Treon SP
J Clin Oncol 2022 Jan 1;40(1):63-71. Epub 2021 Nov 18 doi: 10.1200/JCO.21.01194. PMID: 34793256Free PMC Article
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Sanz RG, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous JV, Motta M, Siddiqi T, Tani M, Trneny M, Minnema MC, Buske C, Leblond V, Trotman J, Chan WY, Schneider J, Ro S, Cohen A, Huang J, Dimopoulos M
Blood 2020 Oct 29;136(18):2038-2050. doi: 10.1182/blood.2020006844. PMID: 32731259Free PMC Article
Ibrutinib in previously treated Waldenström's macroglobulinemia.
Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH
N Engl J Med 2015 Apr 9;372(15):1430-40. doi: 10.1056/NEJMoa1501548. PMID: 25853747

Prognosis

Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol 2023 Feb;98(2):348-358. Epub 2023 Jan 1 doi: 10.1002/ajh.26796. PMID: 36588395Free PMC Article
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol 2021 Feb 1;96(2):258-269. doi: 10.1002/ajh.26082. PMID: 33368476
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Tam CS, Opat S, D'Sa S, Jurczak W, Lee HP, Cull G, Owen RG, Marlton P, Wahlin BE, Sanz RG, McCarthy H, Mulligan S, Tedeschi A, Castillo JJ, Czyz J, Fernández de Larrea C, Belada D, Libby E, Matous JV, Motta M, Siddiqi T, Tani M, Trneny M, Minnema MC, Buske C, Leblond V, Trotman J, Chan WY, Schneider J, Ro S, Cohen A, Huang J, Dimopoulos M
Blood 2020 Oct 29;136(18):2038-2050. doi: 10.1182/blood.2020006844. PMID: 32731259Free PMC Article
Ibrutinib in previously treated Waldenström's macroglobulinemia.
Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL, Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH
N Engl J Med 2015 Apr 9;372(15):1430-40. doi: 10.1056/NEJMoa1501548. PMID: 25853747
Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M; International Myeloma Working Group
Leukemia 2010 Jun;24(6):1121-7. Epub 2010 Apr 22 doi: 10.1038/leu.2010.60. PMID: 20410922Free PMC Article

Clinical prediction guides

Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol 2023 Feb;98(2):348-358. Epub 2023 Jan 1 doi: 10.1002/ajh.26796. PMID: 36588395Free PMC Article
Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial.
Röth A, Berentsen S, Barcellini W, D'Sa S, Jilma B, Michel M, Weitz IC, Yamaguchi M, Nishimura JI, Vos JMI, Storek M, Wong N, Patel P, Jiang X, Vagge DS, Wardęcki M, Shafer F, Lee M, Broome CM
Blood 2022 Sep 1;140(9):980-991. doi: 10.1182/blood.2021014955. PMID: 35687757Free PMC Article
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, Shustik C, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA
J Clin Oncol 2022 Jan 1;40(1):52-62. Epub 2021 Oct 4 doi: 10.1200/JCO.21.00838. PMID: 34606378Free PMC Article
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol 2021 Feb 1;96(2):258-269. doi: 10.1002/ajh.26082. PMID: 33368476
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, Arcaini L, Pinkus GS, Rodig SJ, Sohani AR, Harris NL, Laramie JM, Skifter DA, Lincoln SE, Hunter ZR
N Engl J Med 2012 Aug 30;367(9):826-33. doi: 10.1056/NEJMoa1200710. PMID: 22931316

Recent systematic reviews

First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis.
Abushukair H, Syaj S, Ababneh O, Qarqash A, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Al Hadidi S
Am J Hematol 2022 Jul;97(7):942-950. Epub 2022 Apr 8 doi: 10.1002/ajh.26552. PMID: 35358350
Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis.
Parrondo RD, Reljic T, Iqbal M, Ayala E, Tun HW, Kharfan-Dabaja MA, Kumar A, Murthy HS
Clin Lymphoma Myeloma Leuk 2020 Oct;20(10):e694-e711. Epub 2020 Jun 2 doi: 10.1016/j.clml.2020.05.021. PMID: 32616401
Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled Trials.
Yun S, Vincelette ND, Acharya U, Abraham I
Clin Lymphoma Myeloma Leuk 2017 Jan;17(1):31-37.e13. Epub 2016 Sep 19 doi: 10.1016/j.clml.2016.09.010. PMID: 27780690
Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia.
Vidal L, Gafter-Gvili A, Gurion R, Raanani P, Dreyling M, Shpilberg O
Cochrane Database Syst Rev 2012 Sep 12;2012(9):CD009045. doi: 10.1002/14651858.CD009045.pub2. PMID: 22972131Free PMC Article
Alkylating agents for Waldenstrom's macroglobulinaemia.
Yang K, Tan J, Wu T
Cochrane Database Syst Rev 2009 Jan 21;(1):CD006719. doi: 10.1002/14651858.CD006719.pub3. PMID: 19160296

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Reviews

    Related information

    • OMIM
      Related records in OMIM
    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...